Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
  • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
  • A61K2039/507—Comprising a combination of two or more separate antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Definitions

• This invention relates to an intravesical (i.e. inside the bladder) therapy for bladder cancer.
• Bladder cancer is the ninth most common cancer diagnosis worldwide, with more than 330 000 new cases each year and more than 130 000 deaths per year. At any point in time, 2.7 million people have a history of urinary bladder cancer.
• bladder cancer The diagnosis of bladder cancer ultimately depends on cystoscopic examination of the bladder (cystoscopy) and histological evaluation of the resected tissue. In general, cystoscopy is initially performed in the office, using flexible instruments. At the initial diagnosis of bladder cancer, 70% of cases are diagnosed as non-muscle-invasive bladder cancer (NMIBC) and approximately 30% as muscle-invasive bladder cancer (MIBC).
• NMIBC non-muscle-invasive bladder cancer
• MIBC muscle-invasive bladder cancer
• TUR transurethral resection
• a resection is to completely remove the tumor
• MIBC in case of MIBC; such a resection is of a palliative nature.
• the TUR is also carried out to enable a correct histological diagnosis of the resected tumor/tumor biopsies by a pathologist.
• cystectomy i.e. removal of the bladder and adjacent organs, that is prostate and seminal vesicles in men, and uterus and adnexa in women. It also includes the dissection of regional lymph nodes. Cystectomy is also advocated in patients with NMIBC who are at high risk of progression, i.e. patients having multiple recurrent high-grade tumors or high-grade T1 tumors or high-grade tumors with concurrent carcinoma-in-situ (CIS). Further, cystectomy is advocated in patients with NMIBC who have received Bacillus Calmette-Guérin (BCG) immunotherapy but where such treatment has failed.
• BCG Bacillus Calmette-Guérin
• Neoadjuvant radiotherapy is not recommended according to the current European guidelines on MIBC since no data exist to support that neoadjuvant radiotherapy for operable MIBC increases survival.
• Neoadjuvant chemotherapy has many advantages including that chemotherapy is delivered at the earliest time-point, when the burden of micrometastatic disease is expected to be low; that tolerability of chemotherapy is expected to be better before cystectomy rather than after; and that hypothetically patients with micrometastatic disease might respond to neoadjuvant therapy and reveal favorable pathological status determined mainly by negative lymph node status and negative surgical margins.
• Neoadjuvant cisplatin-containing chemotherapy has shown to significantly improve survival (5% absolute improvement in survival at 5 years).
• delayed cystectomy may compromise the outcome in patients who are not sensitive to chemotherapy and generally, pre-operative anemia and neuropathy is more common in patients receiving neoadjuvant chemotherapy prior to cystectomy.
• neoadjuvant chemotherapy has its limitations regarding patient selection, current development of surgical technique, and current chemotherapy combinations.”
• neoadjuvant therapies for bladder cancer patients who are scheduled for a cystectomy, i.e. bladder cancer patients diagnosed with MIBC or NMIBC who are at high risk of progression, including multiple recurrent high-grade tumors or high-grade T1 tumors or high-grade tumors with concurrent carcinoma-in-situ (CIS).
• the standard treatment is resection of the tumor by TUR.
• Instillation into the bladder of a patient of a composition comprising HAL or a pharmaceutically acceptable salt thereof and exposing the inside of said bladder to blue light may be used to improve visualization of bladder cancer during cystoscopy and/or TUR.
• cystoscopy and TUR are performed using white light.
• photodynamic diagnosis is often used in such procedures.
• PDD involves the administration of a photosensitizer or a precursor thereof (i.e. a “photosensitizing agent”) to an area of interest.
• the photosensitizer or precursor thereof is taken up into the cells, where a precursor of a photosensitizer is converted into an active photosensitizer.
• a precursor of a photosensitizer is converted into an active photosensitizer.
• the photosensitizer Upon exposure of the area of interest to light of a suitable wavelength, the photosensitizer is excited and, upon relaxation to its ground state, fluorescence occurs.
• Hexyl 5-ALA ester hexaminolevulinate, HAL
• HAL preferably penetrates rapidly proliferating cells, e.g. tumor cells, where it is converted into porphyrins, which are photosensitizers and fluorescent compounds. Under subsequent blue-light illumination, the porphyrins emit red light and thus enable specific and accurate visualization of the tumor.
• Hexvix® Photocure ASA, Norway
• Cysview® is a commercially available approved drug that comprises HAL and is used in PDD in cystoscopy and TUR procedures.
• HAL-guided cystoscopy and TUR has increased detection of both papillary tumors and flat carcinoma-in-situ (CIS) lesions, the latter of which are difficult to detect with white light alone.
• HAL-guided TUR of bladder cancer in patients with NMIBC has further reduced the rate of residual tumor after such procedures and has led to superior recurrence free survival (RFS) rates and prolonged RFS intervals compared to white light TUR alone (see Rink M, et al. Eur Urol 4(64), 2013, 624).
• HAL-guided TUR Although a TaT1 tumor can be completely resected by HAL-guided TUR, and HAL-guided TUR favorably affects recurrence rate, these tumors may recur and progress to muscle-invasive bladder cancer in a limited number of cases. It is therefore necessary to consider adjuvant therapy, i.e. adjuvant chemotherapy or adjuvant chemotherapy and adjuvant immunotherapy, in all patients. The choice of therapy may be considered differently according to what risk is acceptable for the individual patient. Usually, a patient will receive one immediate, post-TUR instillation of chemotherapy into the bladder. The need for further adjuvant intravesical therapy depends on the patients' prognosis.
• adjuvant therapy i.e. adjuvant chemotherapy or adjuvant chemotherapy and adjuvant immunotherapy
• a single immediate instillation reduces the risk of recurrence and is considered as the standard treatment, i.e. no further treatment is given in these patients before recurrence.
• a single immediate instillation remains an incomplete treatment because the likelihood of recurrence and/or progression is considerable.
• mitomycin C mitomycin C
• epirubicin epirubicin
• doxorubicin doxorubicin
• Anti-PD-L1 is an investigational monoclonal antibody designed to interfere with a protein called PD-L1.
• Anti-PD-L1 targets PD-L1 expressed on cancer cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on the surface of T cells. By inhibiting PD-L1, anti-PD-L1 may enable the activation of T cells, restoring their ability to effectively detect and attack cancer cells, e.g. bladder cancer cells.
• Anti-PD-1 is an investigational monoclonal antibody that binds to the PD-L1 (programmed death-ligand 1) protein, which is present at high levels in many cancer types, e.g. bladder cancer. By competitively blocking the interaction with PD-1 receptors, it is believed that anti-PD-1 thereby restores anti-cancer T-cell responses.
• PD-L1 programmed death-ligand 1
• anti-PD-L1 antibodies and anti-PD-1 antibodies target different components of the same interaction mechanism between immune cells (specifically killer T cells) and cancer cells, but have a similar therapeutic effect: anti-PD-L1 antibodies target PD-L1 (programmed death ligand-1) expressed on cancer cells while anti-PD-1 antibodies target the other half of this mechanism, PD-1 (programmed death receptor-1), which is expressed on killer T cells.
• PD-L1 programmed death ligand-1
• PD-1 programmeed death receptor-1
• Both anti-PD-L1 antibodies and anti-PD-1 antibodies are for mainly for parenteral or intravenous administration. Such administrations may lead to side effects due to systemic distribution of the drug.
• anti-PD-L1 antibodies and/or anti-PD-1 antibodies are used for intravescial therapy in patients with bladder cancer.
• the invention provides a method of therapy for bladder cancer in a bladder cancer patient comprising the instillation into the bladder of said patient of a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies.
• the invention provides a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies for use in a method of therapy for bladder cancer, wherein said composition is instilled into the bladder of a patient with bladder cancer.
• anti-PD-L1 antibodies and/or anti-PD-1 antibodies means that the composition for use in the invention either comprises anti-PD-L1 antibodies or comprises anti-PD-1 antibodies or comprises both anti-PD-L1 antibodies and anti-PD-1 antibodies.
• Preferred anti-PD-L1 antibodies are those by Roche, preferably MPDL3280A. Said preferred anti-PD-L1 antibodies are described in WO 2010/077634, WO 2013/019906 and WO 2013/181452, the entire contents of which are incorporated herein by reference.
• Preferred anti-PD-1 antibodies are those by Merck, preferably pembrolizumab (Keytruda). Such preferred anti-PD-1 antibodies are described in WO02008/156712, WO 2009/114335 and WO 2013/079174, the entire contents of which are incorporated herein by reference.
• preferred anti-PD-1 antibodies are those by Bristol-Myers Squibb, preferably nivolumab (Opdivo). Such preferred anti-PD-1 antibodies are described in WO 2004/004771, the entire contents of which are incorporated herein by reference.
• the bladder cancer in the context of the invention is either muscular invasive bladder cancer (MIBC) or non-muscular invasive bladder cancer (NMIBC).
• MIBC muscular invasive bladder cancer
• NMIBC non-muscular invasive bladder cancer
• the therapy according to the invention is a neoadjuvant therapy.
• neoadjuvant therapy means the administration of a therapeutic agent before/prior to the main treatment for the disease.
• the main treatment for such patients is cystectomy and the disease is MIBC or NMIBC with a high risk of progression, including multiple recurrent high-grade tumors or high-grade T1 tumors or high-grade tumors with concurrent carcinoma-in-situ (CIS).
• the invention provides a method of neoadjuvant therapy for bladder cancer in a bladder cancer patient who is scheduled for a cystectomy, comprising the instillation into the bladder of said patient of a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies.
• the invention provides a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies for use in a method of neoadjuvant therapy for bladder cancer, wherein said composition is instilled into the bladder of a bladder cancer patient who is scheduled for a cystectomy.
• the therapy according to the invention is an adjuvant therapy.
• adjuvant therapy means the administration of a therapeutic agent in addition to the main treatment for the disease.
• the main treatment for such patients is TUR and the disease is NMIBC where cystectomy is not advocated.
• invention provides a method of adjuvant therapy for bladder cancer in a bladder cancer patient who undergoes TUR, comprising the instillation into the bladder of said patient of a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies.
• the invention provides a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies for use in a method of adjuvant therapy for bladder cancer, wherein said composition is instilled into the bladder of a bladder cancer patient who undergoes TUR.
• the adjuvant therapy according to the invention can be carried out prior, simultaneously or after said TUR.
• the composition for use in the invention may comprise pharmaceutically acceptable carriers, excipients, or stabilizers.
• the composition for use in the invention is preferably a semi-solid composition or a liquid composition.
• semi-solid denotes a physical state which is neither solid nor liquid.
• Semi-solids (or quasi-solids) are similar to a solid in some respects, e.g. a semi-solid can support its own weight and hold its shape but also shares some properties of liquids, such as shape conformity to something applying pressure to it, or the ability to flow under pressure.
• Semi-solids are characterized by a three-dimensional structure that is sufficient to impart solid-like character to the undisturbed system but that is easily broken down and realigned under an applied force.
• Semi-solids have a rigidity and viscosity intermediate between a solid and a liquid.
• Preferred semi-solid compositions are foams, gels and lotions, preferably low viscosity gels and lotions.
• liquid compositions are preferred, especially liquid compositions that are solutions or suspensions of anti-PD-L1 antibodies and/or anti-PD-1 antibodies, i.e. more preferably comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies in a liquid carrier.
• Preferred liquid carriers are water or aqueous solutions, most preferably aqueous buffers.
• composition for use in the invention is a liquid composition comprising water
• pH of said composition is preferably in the range of 4.5 to 7.5.
• composition for use in the invention preferably comprises a therapeutically effective amount of anti-PD-L1 antibodies and/or anti-PD-1 antibodies.
• therapeutically effective amount can be administered in one or more instillations into the bladder.
• a therapeutically effective amount of anti-PD-L1 antibodies and/or anti-PD-1 antibodies is an amount sufficient to accomplish therapeutic treatment together with at least the main treatment, i.e. cystectomy or TUR.
• Other neoadjuvant or adjuvant treatments may be carried out together with the therapy of the invention, e.g. neoadjuvant radiotherapy, (neo)adjuvant chemotherapy or (neo)adjuvant immunotherapy.
• the amount of the composition for use in the invention which is instilled into the bladder may vary according to the bladder volume and size of the bladder of the patient. In general, a volume of about 50 ml of the composition is instilled.
• composition for use in the invention is instilled preferably into the empty bladder through a catheter and is left in the bladder from about 20 minutes to about 3 hours, more preferably from about 30 minutes to about 2 hours, most preferably no less than 1 hour.
• composition of the invention further comprises hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof.
• HAL hexyl 5-ALA ester
• HAL-guided TUR in patients with NMIBC has led to superior recurrence free survival (RFS) rates and prolonged RFS intervals compared to white light TUR alone.
• RFS recurrence free survival
• HAL-guided TUR in patients with MIBC seem to have an impact on recurrence free survival: in 268 consecutive patients who underwent cystectomy for bladder cancer it was retrospectively investigated whether patients prior to the cystectomy had undergone HAL-guided TUR or whether TUR was carried out with white light alone.
• Kaplan-Meier analysis was used to estimate recurrence-free survival (RFS) and overall survival (OS). The 3-year RFS was 69.8% in patients with HAL-guided TUR and 58.2% in patients with white light TUR alone.
• composition which further comprises hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof and wherein after instillation of said composition into the bladder of said patient the inside of said bladder is exposed to light.
• HAL hexyl 5-ALA ester
• the invention provides a method of therapy for bladder cancer in a bladder cancer patient comprising (i) the instillation into the bladder of said patient of a composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof and (ii) exposing the inside of said bladder to light.
• a composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof and (ii) exposing the inside of said bladder to light.
• HAL hexyl 5-ALA ester
• the invention provides a composition
• a composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof for use in a method of therapy for bladder cancer, said therapy comprising (i) instillation of said composition into the bladder of a patient with bladder cancer and (ii) exposing the inside of said bladder to light.
• HAL hexyl 5-ALA ester
• 5-ALA denotes 5-aminolevulinic acid, i.e. 5-amino-4-oxo-pentanoic acid.
• hexyl 5-ALA ester denotes n-hexyl aminolevulinate, i.e. n-hexyl 5-amino-4-oxo-pentanoate.
• pharmaceutically acceptable salt denotes a salt that is suitable for use in the dry pharmaceutical product and which fulfils the requirements related to for instance safety, bioavailability and tolerability (see for instance P. H. Stahl et al. (eds.) Handbook of Pharmaceutical Salts, Publisher Helvetica Chimica Acta, Zurich, 2002).
• hexyl 5-ALA ester The synthesis of hexyl 5-ALA ester is known in the art and may be prepared as described in e.g. WO 96/28412, the entire contents of which are incorporated herein by reference. Briefly, hexyl 5-ALA ester may be prepared by reaction of 5-ALA with hexanol in the presence of a catalyst, e.g. an acid. Further, hexyl 5-ALA ester hydrochloride is commercially available, e.g. in the form of Hexvix® (Photocure ASA and Ipsen Pharma SA) or Cysview® (Photocure Inc.).
• the hexyl 5-ALA ester for use in embodiments of the invention is preferably in the form of a pharmaceutically acceptable salt.
• Such salts are preferably acid addition salts with pharmaceutically acceptable organic or inorganic acids.
• Suitable acids include, for example, hydrochloric, nitric, hydrobromic, phosphoric, sulfuric, sulfonic acid and sulfonic acid derivatives, the salts of ALA-esters and the latter acids are described in WO 2005/092838 to Photocure ASA, the entire contents of which are incorporated herein by reference.
• a preferred acid is hydrochloride acid, HC1. Synthetic procedures for salt formation are conventional in the art and are for instance described in WO 2005/092838.
• the concentration of HAL in the composition for use in the invention is conveniently in the range of 0.1 to 5% by weight of the total weight of the composition or the equivalent concentration of a pharmaceutically acceptable salt of HAL, preferably 0.15 to 3.5%, and most preferably 0.17%.
• the hydrochloride salt of HAL is used in the composition at a concentration of 0.2%.
• the composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) HAL or a pharmaceutically acceptable salt thereof for use in the invention is a liquid composition.
• Preferred liquid carriers are water or aqueous solutions, most preferably aqueous buffers.
• the liquid carrier is an aqueous phosphate buffer, preferably an aqueous phosphate buffer which comprises disodium phosphate dehydrate, potassium dihydrogen phosphate, sodium chloride, hydrochloric acid, sodium hydroxide and water.
• aqueous phosphate buffer which comprises disodium phosphate dehydrate, potassium dihydrogen phosphate, sodium chloride, hydrochloric acid, sodium hydroxide and water.
• the composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) HAL or a pharmaceutically acceptable salt thereof for use in the invention is a composition comprising water, said composition has a pH in the range of 4.5 to 7.5, more preferably in the range of 5.7 and 7.2.
• the amount of the composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) HAL or a pharmaceutically acceptable salt thereof, which is instilled into the bladder, may vary according to the bladder volume and size of the bladder of the patient. In general, a volume of about 50 ml of the composition is instilled.
• composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) HAL or a pharmaceutically acceptable salt thereof for use in the invention is instilled preferably into the empty bladder through a catheter and is left in the bladder from about 20 minutes to about 3 hours, more preferably from about 30 minutes to about 2 hours, most preferably no less than 1 hour. If the patient cannot retain the composition for 1 hour, at least 1 hour should be allowed to pass from the instillation of the composition into the bladder to the start of exposing the inside of the bladder to light.
• any wavelength of light which is suitable to excite the hexyl 5-ALA ester may be used.
• white light i.e. visible light with wavelengths of from about 350 to 700 nm and/or blue light, i.e. wavelengths of from about 360 nm to about 450 nm and/or red light, i.e. wavelengths of from about 600 to 670 nm.
• the term and/or means that e.g. the inside of the bladder is exposed to either white or blue light or to white light and blue light, subsequently and not at the same time.
• white light and/or blue light more preferred white light followed by blue light.
• cystoscopic light sources For exposing the inside of the bladder to light, approved cystoscopic light sources are preferred which allow both for white light and blue light irradiation of the inside of the bladder.
• cystoscopes are commercially available, e.g. from Karl Storz (Photodynamic Diagnostic D-Light C (PDD) System), Olympus or Richard Wolf).
• PDD Photodynamic Diagnostic D-Light C
• Richard Wolf For red light irradiation, such equipment may be modified with the suitable filters.
• cystoscopic light sources may be rigid or flexible.
• the light dose given during irradiation of the inside of the bladder with use of white and blue light may vary but is preferably 0.01 to 100 J/cm2, more preferably 0.03-40 J/cm 2 and most preferably 0.1 to 3 J/cm 2 .
• a cystoscopic light source with a output in the range of 47-82 mW such a light dose is provided in about 10 to 30 minutes (calculated based on a 300 cm 2 surface area for a human bladder).
• the method of therapy according to the invention may be used as a neoadjuvant therapy for bladder cancer patients who are scheduled for a cystectomy.
• the invention provides a method of neoadjuvant therapy for bladder cancer in a bladder cancer patient who are scheduled for a cystectomy, said method comprising (i) the instillation into the bladder of said patient of a composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof and (ii) exposing the inside of said bladder to light.
• a composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof and (ii) exposing the inside of said bladder to light.
• HAL hexyl 5-ALA ester
• the invention provides a composition
• a composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof for use in a method of neoadjuvant therapy for bladder cancer, said therapy comprising (i) instillation of said composition into the bladder of a patient with bladder cancer who is scheduled for a cystectomy; and (ii) exposing the inside of said bladder to light.
• HAL hexyl 5-ALA ester
• the time between the method of neoadjuvant therapy of the invention, i.e. instillation into the bladder of a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies or a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) HAL or a pharmaceutically acceptable salt thereof and exposing the inside of said bladder to light and the cystectomy may vary but is preferably zero to 6 weeks, e.g. zero to 1, 2, 3, 4, 5 or 6 weeks and more preferably zero to 3 weeks, e.g. 1 or 2 weeks. “Zero” means that the cystectomy is carried out directly after the light irradiation is finalized. This has the advantage that the patient is only anaesthetized once.
• bladder cancer patients who are scheduled for a cystectomy are those diagnosed with MIBC or NMIBC with a high risk of progression, including multiple recurrent high-grade tumors or high-grade T1 tumors or high-grade tumors with concurrent carcinoma-in-situ (CIS).
• CIS carcinoma-in-situ
• the neoadjuvant therapy of the invention may be carried out once or repeatedly prior to the cystectomy, i.e. carried out two or more times, e.g. 3, 4, 5 or 6 times, with a period between the treatments of e.g. 4 days to 4 weeks, e.g. 1, 2 or 3 weeks.
• neoadjuvant therapy of the invention may be carried out prior, simultaneously or after other neoadjuvant therapies, including neoadjuvant radiotherapy, neoadjuvant chemotherapy (intravescial instillation or systemic administration) with e.g. cisplatin, methotrexate, vinblastine, valurubicin, adriamycin, mitomycin C or combinations thereof and neoadjuvant immunotherapy (intravescial instillation or systemic administration) with e.g. BCG.
• neoadjuvant radiotherapy eoadjuvant chemotherapy (intravescial instillation or systemic administration) with e.g. cisplatin, methotrexate, vinblastine, valurubicin, adriamycin, mitomycin C or combinations thereof
• neoadjuvant immunotherapy intraavescial instillation or systemic administration
• the patient may receive systemic adjuvant chemotherapy with e.g. cisplatin, methotrexate, vinblastine, adriamycin, gemcitabine, doxorubicin, epirubicin, cyclophosphamide or combinations thereof.
• systemic adjuvant chemotherapy e.g. cisplatin, methotrexate, vinblastine, adriamycin, gemcitabine, doxorubicin, epirubicin, cyclophosphamide or combinations thereof.
• systemic adjuvant immunotherapy e.g. anti-PD-L1 antibodies and/or anti-PD-1 antibodies.
• the method of therapy according to the invention may be used as an adjuvant therapy for bladder cancer patients who undergo TUR, i.e. patients who are diagnosed with NMIBC.
• the invention provides a method of adjuvant therapy for bladder cancer in a bladder cancer patient who undergoes TUR, said method comprising (i) the instillation into the bladder of said patient of a composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof and (ii) exposing the inside of said bladder to light.
• a composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof and (ii) exposing the inside of said bladder to light.
• HAL hexyl 5-ALA ester
• the invention provides a composition
• a composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof for use in a method of adjuvant therapy for bladder cancer, said therapy comprising (i) instillation of said composition into the bladder of a patient with bladder cancer who undergoes TUR; and (ii) exposing the inside of said bladder to light.
• HAL hexyl 5-ALA ester
• the time between said TUR and the adjuvant therapy of the invention, i.e. instillation into the bladder of a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies is preferably zero to 6 weeks, e.g. zero to 1, 2, 3, 4, 5 or 6 weeks and more preferably zero to 3 weeks, e.g. 1 or 2 weeks. “Zero” means that the adjuvant therapy according to the invention is carried out directly after said TUR.
• the adjuvant therapy according to the invention comprises the instillation into the bladder of a composition comprising a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) HAL or a pharmaceutically acceptable salt thereof and exposing the inside of said bladder to light
• the TUR may be is carried out simultaneously with said therapy, since the use of HAL enables detection and thus accurate resection of the tumor.
• the adjuvant therapy of the invention may be carried out prior, simultaneously or after other neoadjuvant or adjuvant therapies, including (neo)adjuvant radiotherapy, (neo)adjuvant chemotherapy (intravescial instillation or systemic administration) with e.g. cisplatin, methotrexate, vinblastine, valurubicin, adriamycin, mitomycin C or combinations thereof and (neo)adjuvant immunotherapy (intravescial instillation or systemic administration) with e.g. BCG or anti-PD-L1 antibodies and/or anti-PD-1 antibodies.
• neoadjuvant radiotherapy e.g. cisplatin, methotrexate, vinblastine, valurubicin, adriamycin, mitomycin C or combinations thereof
• neo)adjuvant immunotherapy intraavescial instillation or systemic administration

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Cell Biology (AREA)
• Urology & Nephrology (AREA)
• Reproductive Health (AREA)
• Gynecology & Obstetrics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Orthopedics, Nursing, And Contraception (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=55311161

Family Applications (2)

Family Applications After (1)

Country Status (10)

Cited By (1)

Families Citing this family (3)

Citations (3)

Family Cites Families (9)

• 2015
  • 2015-12-17 GB GBGB1522311.8A patent/GB201522311D0/en not_active Ceased
• 2016
  • 2016-12-19 AU AU2016372570A patent/AU2016372570B2/en active Active
  • 2016-12-19 CA CA3008548A patent/CA3008548A1/en active Pending
  • 2016-12-19 EP EP16819062.7A patent/EP3390448B1/en active Active
  • 2016-12-19 BR BR112018012116A patent/BR112018012116A2/pt active Search and Examination
  • 2016-12-19 JP JP2018532038A patent/JP2018538308A/ja active Pending
  • 2016-12-19 WO PCT/EP2016/081798 patent/WO2017103280A1/en active Application Filing
  • 2016-12-19 KR KR1020187020008A patent/KR20180094988A/ko unknown
  • 2016-12-19 CN CN201680079683.1A patent/CN108699147B/zh active Active
  • 2016-12-19 US US16/063,169 patent/US20180371101A1/en not_active Abandoned
• 2019
  • 2019-04-18 US US16/388,379 patent/US11066478B2/en active Active

Patent Citations (4)

Also Published As

Similar Documents

Legal Events